Prevalence of metabolic syndrome in patients with pso
study

British Journal of Dermatology

157, 68-73

DOI: 10.1111/j.1365-2133.2007.07986.x

Citation Report

#	Article	IF	Citations
3	The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis. Archives of Dermatological Research, 2008, 300, 545-550.	1.1	12
4	Balneotherapy for chronic plaque psoriasis at Comano spa in Trentino, Italy. Dermatologic Therapy, 2008, 21, S31-S38.	0.8	29
5	The relation between high-sensitivity C-reactive protein and maximum body mass index in patients with psoriasis. British Journal of Dermatology, 2008, 158, 1141-1143.	1.4	18
7	Long-term prognosis in patients with psoriasis. British Journal of Dermatology, 2008, 159, 2-9.	1.4	101
8	Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. British Journal of Dermatology, 2008, 159, 10-17.	1.4	190
9	Psoriasis and the risk of incident diabetes mellitus: a population-based study. British Journal of Dermatology, 2008, 159, 1331-1337.	1.4	95
10	AJC Editor's Consensus: Psoriasis and Coronary Artery Disease. American Journal of Cardiology, 2008, 102, 1631-1643.	0.7	148
11	Efalizumab in the treatment of psoriasis: when comorbidity is an issue. Dermatologic Therapy, 2008, 21, S25-S29.	0.8	4
14	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal of the American Academy of Dermatology, 2008, 58, 1031-1042.	0.6	383
15	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2008, 58, 826-850.	0.6	1,128
17	Targeting tumor necrosis factor Î± in psoriasis and psoriatic arthritis. Expert Opinion on Therapeutic Targets, 2008, 12, 1085-1096.	1.5	58
18	Medical History, Drug Exposure and the Risk of Psoriasis. Dermatology, 2008, 216, 125-132.	0.9	42
19	Psoriasis and Metabolic Comorbidities: The Importance of Well-Designed Prospective Studies. Dermatology, 2008, 217, 222-224.	0.9	8
20	Psoriasis as a systemic disease. Expert Review of Dermatology, 2008, 3, S25-S29.	0.3	0
21	Psoriasis and metabolic disease: epidemiology and pathophysiology. Current Opinion in Rheumatology, 2008, 20, 416-422.	2.0	223
22	Cardiometabolic risk in psoriasis: differential effects of biologic agents. Vascular Health and Risk Management, 2008, Volume 4, 1229-1235.	1.0	17
23	Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Therapeutics and Clinical Risk Management, 2008, Volume 4, 559-568.	0.9	67
24	Psoriasis â€“ New Insights Into Pathogenesis and Treatment. Deutsches Ärzteblatt International, 2009, 106, 11-8, quiz 19.	0.6	61

#	Article	IF	Citations
25	Chronic Plaque Psoriasis Is Associated with Increased Arterial Stiffness. Dermatology, 2009, 218, 110-113.	0.9	109
26	Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. Dermatology, 2009, 219, 158-161.	0.9	6
27	Psoriasis in France and Associated Risk Factors: Results of a Case-Control Study Based on a Large Community Survey. Dermatology, 2009, 218, 103-109.	0.9	76
28	Psoriasis and Atherothrombotic Diseases: Disease-Specific and Nonâ€“Disease-Specific Risk Factors. Seminars in Thrombosis and Hemostasis, 2009, 35, 313-324.	1.5	86
29	Impact of Comorbidities on the Management of Psoriasis. Current Problems in Dermatology, 2009, 38, 21-36.	0.8	19
32	Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. International Journal of Dermatology, 2009, 48, 1147-1156.	0.5	35
33	Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. British Journal of Dermatology, 2009, 160, 1048-1056.	1.4	162
34	More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. British Journal of Dermatology, 2009, 161, 1-7.	1.4	116
35	Psoriasis â€“ a systemic inflammatory disorder: clinic, pathogenesis and therapeutic perspectives. JDDG - Journal of the German Society of Dermatology, 2009, 7, 946-952.	0.4	18
36	Psoriasis Ã¢Â€Â“ eine systemische EntzÃƒÂ¼ndung: Klinik, Pathogenese und Therapieziele. JDDG - Journal of the German Society of Dermatology, 2009, 7, 946-952.	0.4	26
37	Effects of tumor necrosis factor-Î± blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatologic Therapy, 2009, 22, 61-73.	0.8	80
38	Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1-6.	1.3	167
39	Psoriasis and systemic inflammation: underdiagnosed enthesopathy. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 3-8.	1.3	57
40	Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a populationâ€based sample. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 885-892.	1.3	102
41	Cardiometabolic Comorbidities and the Approach to Patients with Psoriasis. Actas Dermo-sifiliogrÃ¡ficas, 2009, 100, 14-21.	0.2	26
42	Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. Journal of Hepatology, 2009, 51, 758-764.	1.8	217
43	Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. Journal of Hepatology, 2009, 51, 778-786.	1.8	209
44	Comorbidities in Patients with Psoriasis. American Journal of Medicine, 2009, 122, 1150.e1-1150.e9.	0.6	161

#	Article	IF	Citations
45	Prevalence of obesity/adiposity in Japanese psoriasis patients: Adiposity is correlated with the severity of psoriasis. Journal of Dermatological Science, 2009, 54, 61-63.	1.0	21
46	Erratum to â€œPrevalence of obesity/adiposity in Japanese psoriasis patients: Adiposity is correlated with the severity of psoriasisâ€•[J. Dermatol. Sci. 54 (2009) 61â€“63]. Journal of Dermatological Science, 2009, 55, 74-76.	1.0	32
47	Psoriasis. New England Journal of Medicine, 2009, 361, 496-509.	13.9	2,498
48	Ustekinumab. Drugs, 2009, 69, 1141-1152.	4.9	30
49	Comorbidities in Dermatology. Dermatologic Clinics, 2009, 27, 137-147.	1.0	35
50	Burden of skin diseases. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 271-283.	0.7	96
51	Skin Integrity in Critically Ill Obese Patients. Critical Care Nursing Clinics of North America, 2009, 21, 311-322.	0.4	27
52	Evaluation and Management of Psoriasis: An Internist's Guide. Medical Clinics of North America, 2009, 93, 1291-1303.	1.1	50
53	Psoriasis y sÃndrome metabÃ³lico. Piel, 2010, 25, 133-145.	0.0	7
54	Usefulness of the Framingham Risk Score in Patients With Chronic Psoriasis. American Journal of Cardiology, 2010, 106, 1754-1757.	0.7	53
55	Psoriasis and the metabolic syndrome. Dermatologic Therapy, 2010, 23, 137-143.	0.8	59
56	Psoriasis and cardiovascular disease. Dermatologic Therapy, 2010, 23, 144-151.	0.8	95
57	Psoriasis, the liver, and the gastrointestinal tract. Dermatologic Therapy, 2010, 23, 155-159.	0.8	35
58	Psoriasis and serum lipid abnormalities. Dermatologic Therapy, 2010, 23, 160-173.	0.8	26
59	The prevalence of the obesity in patients with moderate to severe psoriasis in Sicily populations. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 92-93.	1.3	14
60	Evidenceâ€based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 2-9.	1.3	62
61	Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 23-30.	1.3	119
62	Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1386-1394.	1.3	104

#	Article	IF	Citations
63	Exploring the association between cardiovascular and other diseaseâ€related risk factors in the psoriasis population: the need for increased understanding across the medical community. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1371-1377.	1.3	39
64	Psoriasis: is the impairment to a patientâ€™s life cumulative?. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 989-1004.	1.3	180
67	EADV preceptorship: advances in dermatology. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 2-24.	1.3	11
68	Comorbidities associated with psoriasis: An experience from the Middle East. Journal of Dermatology, 2010, 37, 146-155.	0.6	135
70	British Journal of Dermatology : a fresh complexion. British Journal of Dermatology, 2010, 162, 1-3.	1.4	2
71	Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evidence, 2010, 5, 11.	4.7	11
72	Psoriasis is a Disease with Serious Comorbidities. Psoriasis Forum, 2010, 16a, 21-26.	0.1	0
73	Association between Psoriasis and Cardiovascular Risk Factors in Korean Patients. Annals of Dermatology, 2010, 22, 300.	0.3	40
74	PsorÃase e obesidade: revisÃ£o de literatura e recomendaÃ§Ãµes no manejo. Anais Brasileiros De Dermatologia, 2010, 85, 355-360.	0.5	37
75	The psoriasiform reaction pattern. , 2010, , 71-91.e18.		4
76	Challenging Cases in Allergic and Immunologic Diseases of the Skin. , 2010, , .		4
77	Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis. Journal of Rheumatology, 2010, 37, 1386-1394.	1.0	114
78	Increased Prevalence of the Metabolic Syndrome in Patients with Psoriatic Arthritis. Metabolic Syndrome and Related Disorders, 2010, 8, 331-334.	0.5	96
79	Prevalence of metabolic syndrome in patients with psoriasis. Indian Journal of Dermatology, Venereology and Leprology, 2010, 76, 662.	0.2	83
80	Psoriasis in India: Prevalence and pattern. Indian Journal of Dermatology, Venereology and Leprology, 2010, 76, 595.	0.2	139
81	Psoriasis and Hypertension: A Case-Control Study. Acta Dermato-Venereologica, 2010, 90, 23-26.	0.6	79
82	Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany. Acta Dermato-Venereologica, 2010, 90, 147-151.	0.6	265
83	Lipid Disturbances in Psoriasis: An Update. Mediators of Inflammation, 2010, 2010, 1-13.	1.4	98

#	Article	IF	Citations
84	High Body Mass Index in Adolescent Girls Precedes Psoriasis Hospitalization. Acta Dermato-Venereologica, 2010, 90, 488-493.	0.6	37
85	Increased Amount of Visceral Fat in Patients with Psoriasis Contributes to Metabolic Syndrome. Dermatology, 2010, 220, 32-37.	0.9	42
86	Prevalence of Acne Vulgaris in Patients with Down Syndrome. Dermatology, 2010, 220, 333-339.	0.9	8
87	Homocysteine, Vitamin B₁₂ and Folic Acid Levels in Psoriatic Patients and Correlation with Disease Severity. International Journal of Immunopathology and Pharmacology, 2010, 23, 911-916.	1.0	42
88	C-Reactive Protein and Markers for Thrombophilia in Patients with Chronic Plaque Psoriasis. International Journal of Immunopathology and Pharmacology, 2010, 23, 1195-1202.	1.0	31
92	The therapeutic potential of TNF-Î± antagonists for skin psoriasis comorbidities. Expert Opinion on Biological Therapy, 2010, 10, 1197-1208.	1.4	19
93	Prevalence of metabolic syndrome in Japanese psoriasis patients. Journal of Dermatological Science, 2010, 57, 143-144.	1.0	52
94	Mutational survey of recessive dystrophic epidermolysis bullosa in Tunisian families unveils a spectrum of private, ethnic specific and world wide recurrent mutations. Journal of Dermatological Science, 2010, 57, 144-146.	1.0	4
95	Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology, 2010, 63, 1058-1069.	0.6	102
96	Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine, 2010, 49, 163-170.	1.4	44
100	Comorbidities in Psoriasis Patients. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 10-15.	1.6	99
101	Hepatoprotective effect of tumour necrosis factor Î± blockade in psoriatic arthritis: a cross-sectional study. Annals of the Rheumatic Diseases, 2010, 69, 1148-1150.	0.5	34
103	Cardiovascular Risk Factors in Patients with Lichen Planus. American Journal of Medicine, 2011, 124, 543-548.	0.6	81
104	Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology, 2011, 65, 537-545.	0.6	65
105	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2011, 65, 137-174.	0.6	398
106	Vascular endothelial function assessed by a noninvasive ultrasound method and serum asymmetric dimethylarginine concentrations in mild-to-moderate plaque-type psoriatic patients. Clinical Biochemistry, 2011, 44, 1080-1084.	0.8	15
107	Role of serum uric acid in conditioning the association of psoriasis with metabolic syndrome. European Journal of Dermatology, 2011, 21, 808-809.	0.3	11
109	Do eating disorders accompany metabolic syndrome in psoriasis patients? Results of a preliminary study. Clinical, Cosmetic and Investigational Dermatology, 2011, 4, 139.	0.8	6

#	Article	IF	Citations
110	Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study. European Journal of Dermatology, 2011, 21, 761-770.	0.3	32
111	Subcutaneous injection of isophane protamine biosynthetic human insulin induced psoriasis at the injection site. European Journal of Dermatology, 2011, 21, 807-808.	0.3	6
112	Endothelial dysfunction in psoriasis patients: cross-sectional case-control study. European Journal of Dermatology, 2011, 21, 510-514.	0.3	23
114	A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. British Journal of Dermatology, 2011, 164, 26-32.	1.4	32
115	Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. British Journal of Dermatology, 2011, 164, 1-14.	1.4	113
116	Obesity and the skin. British Journal of Dermatology, 2011, 165, 743-750.	1.4	121
117	Homocysteine status and cardiovascular risk factors in patients with psoriasis: a caseâ€“control study. Clinical and Experimental Dermatology, 2011, 36, 19-23.	0.6	27
118	Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. Clinical and Experimental Dermatology, 2011, 36, 473-478.	0.6	43
119	Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. Journal of Internal Medicine, 2011, 270, 237-244.	2.7	56
120	Psoriasis and nonâ€alcoholic fatty liver disease. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 383-391.	1.3	55
121	Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 705-709.	1.3	48
122	Pregnancy outcomes in women with moderateâ€toâ€severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1041-1047.	1.3	53
123	Lipid levels in patients with lichen planus: a caseâ€“control study. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1398-1401.	1.3	44
124	Strategies for improving the quality of care in psoriasis with the use of treatment goals â€“ a report on an implementation meeting. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1-13.	1.3	44
125	Association between the leptin gene 2548G/A polymorphism, the plasma leptin and the metabolic syndrome with psoriasis. Experimental Dermatology, 2011, 20, 715-719.	1.4	44
126	S3 - Guidelines on the treatment of psoriasis vulgaris Update 2011. JDDG - Journal of the German Society of Dermatology, 2011, 9, S1-S95.	0.4	66
128	The Association of Psoriasis and Elevated Blood Lipids in Overweight and Obese Children. Journal of Pediatrics, 2011, 159, 577-583.	0.9	98
129	Atorvastatin for the Treatment of Plaqueâ€Type Psoriasis. Pharmacotherapy, 2011, 31, 1045-1050.	1.2	23

#	Article	IF	Citations
130	Influence of endothelial nitric oxide synthase polymorphisms in psoriasis risk. Archives of Dermatological Research, 2011, 303, 445-449.	1.1	16
131	Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Archives of Dermatological Research, 2011, 303, 451-455.	1.1	74
132	Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia, 2011, 54, 2745-2754.	2.9	118
133	Psoriasis and Vascular Diseaseâ€"Risk Factors and Outcomes: A Systematic Review of the Literature. Journal of General Internal Medicine, 2011, 26, 1036-1049.	1.3	73
134	Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care and Research, 2011, 63, 195-202.	1.5	165
135	Serum paraoxonaseâ€1 activities and oxidative status in patients with plaqueâ€type psoriasis with/without metabolic syndrome. Journal of Clinical Laboratory Analysis, 2011, 25, 289-295.	0.9	22
136	Prevalence of the Metabolic Syndrome in Psoriasis. Archives of Dermatology, 2011, 147, 419.	1.7	236
137	Patients with Psoriasis Have a Higher Prevalence of Parental Cardiovascular Disease. Dermatology, 2011, 222, 330-335.	0.9	11
138	Patch test results from a contact dermatitis clinic in North India. Indian Journal of Dermatology, Venereology and Leprology, 2011, 77, 194.	0.2	7
139	Systemic Role for Vitamin D in the Treatment of Psoriasis and Metabolic Syndrome. Dermatology Research and Practice, 2011, 2011, 1-4.	0.3	28
140	Prevalence of metabolic syndrome in patients with psoriasis. Indian Journal of Dermatology, Venereology and Leprology, 2011, 77, 193.	0.2	8
141	A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis. Journal of Investigative Dermatology, 2012, 132, 304-314.	0.3	157
142	Plasma and tissue chemerin levels and their relation to metabolic syndrome in patients with psoriasis. Journal of the Egyptian Women's Dermatologic Society, 2012, 9, 118-122.	0.2	0
143	Psoriasis vulgaris severity and body mass index. Journal of the Egyptian Women's Dermatologic Society, 2012, 9, 86-91.	0.2	0
144	Biochemical markers of psoriasis as a metabolic disease. Folia Histochemica Et Cytobiologica, 2012, 50, 155-170.	0.6	30
145	Psoriasis and Risk of Type 2 Diabetes among Women and Men in the United States: A Population-Based Cohort Study. Journal of Investigative Dermatology, 2012, 132, 291-298.	0.3	54
146	Psoriasis ve Obezite. Turkderm, 2012, 46, 3-6.	0.0	2
147	Metabolic syndrome in psoriasis. Advances in Dermatology and Allergology, 2012, 5, 356-362.	1.0	2

#	Article	IF	Citations
148	Weight Reduction Alone May Not Be Sufficient to Maintain Disease Remission in Obese Patients with Psoriasis: A Randomized, Investigator-Blinded Study. Dermatology, 2012, 224, 31-37.	0.9	29
149	â˜'174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-Î± blockers. Pharmacogenetics and Genomics, 2012, 22, 134-142.	0.7	41
150	Atheroma plaque, metabolic syndrome and inflammation in patients with psoriasis. European Journal of Dermatology, 2012, 22, 337-344.	0.3	59
151	Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. British Journal of Dermatology, 2012, 167, 668-677.	1.4	281
154	Metabolic Syndrome in Patients with Psoriatic Disease. Journal of rheumatology Supplement, The, 2012, 89, 24-28.	2.2	74
156	Psoriasis and cardiovascular risk factors: AÂcase-control study on inpatients comparing psoriasis to dermatitis. Journal of the American Academy of Dermatology, 2012, 66, 252-258.	0.6	57
157	Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes and Metabolism, 2012, 38, 86-88.	1.4	32
158	Integrated Approach to Comorbidity in Patients With Psoriasis. Actas Dermo-sifiliogrÃ¡ficas, 2012, 103, 1-64.	0.2	8
159	Multiplatform Application to Determine Presence of Metabolic Syndrome and Cardiovascular Risk in Patients With Psoriasis. Actas Dermo-sifiliogrÃ¡ficas, 2012, 103, 111-119.	0.2	0
160	Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists. Journal of the American Academy of Dermatology, 2012, 67, 357-362.	0.6	57
161	Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions. Journal of Dermatological Science, 2012, 68, 199-202.	1.0	11
162	Pharmacogenetic Analysis of TNF, TNFRSF1A, and TNFRSF1B Gene Polymorphisms and Prediction of Response to Anti-TNF Therapy in Psoriasis Patients in the Greek Population. Molecular Diagnosis and Therapy, 2012, 16, 29-34.	1.6	72
163	Prevalence of Metabolic Syndrome in Patients with Psoriasis. Scientific World Journal, The, 2012, 2012, 1-5.	0.8	46
164	Cardiovascular Disease in Inflammatory Disorders - Psoriasis and Psoriatic Arthritis. , 2012, , .		0
165	Metabolic Features in Psoriasis. , 0, , .		0
166	Analysis of Cardiovascular Risk Factors and Metabolic Syndrome in Korean Patients with Psoriasis. Annals of Dermatology, 2012, 24, 11.	0.3	39
167	Psoriasis: epidemiology, natural history, and differential diagnosis. Psoriasis: Targets and Therapy, 2012, , 67.	1.2	6
168	Application of the dermatology life quality index in clinical trials of biologics for psoriasis. Chinese Journal of Integrative Medicine, 2012, 18, 179-185.	0.7	13

#	Article	IF	Citations
169	Cardiovascular Mortality in Psoriasis and Psoriatic Arthritis: Epidemiology, Pathomechanisms, Therapeutic Implications, and Perspectives. Current Rheumatology Reports, 2012, 14, 343-348.	2.1	54
170	Association between psoriasis and chronic obstructive pulmonary disease: a populationâ€based study in Taiwan. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 59-65.	1.3	41
171	Influence of severity of the cutaneous manifestations and age on the prevalence of several cardiovascular risk factors in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 348-353.	1.3	32
172	Psoriasis and hypertension: a caseâ€control study. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 785-788.	1.3	28
173	The concept of psoriasis as a systemic inflammation: implications for disease management. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 3-11.	1.3	253
174	Psoriasis and physical activity: a review. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1345-1353.	1.3	35
175	Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor. Australasian Journal of Dermatology, 2012, 53, 70-72.	0.4	14
176	Psoriasis and type 2 diabetes risk among psoriatic patients in a Spanish population. Australasian Journal of Dermatology, 2012, 53, 128-130.	0.4	23
177	Vitamin D status in patients with chronic plaque psoriasis. British Journal of Dermatology, 2012, 166, 505-510.	1.4	120
178	Leptin, adiponectin, visfatin and retinolâ€binding proteinâ€4 â€“ mediators of comorbidities in patients with psoriasis?. Experimental Dermatology, 2012, 21, 43-47.	1.4	78
179	S3 â€“ Guidelines on the treatment of psoriasis vulgaris (English version). Update. JDDG - Journal of the German Society of Dermatology, 2012, 10, S1-95.	0.4	235
180	Psoriasis and metabolic syndrome. Journal of Dermatology, 2012, 39, 212-218.	0.6	100
181	Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. British Journal of Dermatology, 2012, 167, 436-439.	1.4	56
182	Modifiable lifestyle factors associated with metabolic syndrome in patients with psoriasis. Clinical and Experimental Dermatology, 2012, 37, 477-483.	0.6	23
183	The role of pigment epithelium-derived factor as an adipokine in psoriasis. Archives of Dermatological Research, 2012, 304, 81-84.	1.1	6
184	Psoriasis increased the risk of diabetes: a meta-analysis. Archives of Dermatological Research, 2012, 304, 119-125.	1.1	39
185	Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e30-41.	1.3	75
186	Cardiovascular risk factors in subjects with psoriasis: a crossâ€sectional general population study. International Journal of Dermatology, 2013, 52, 681-683.	0.5	21

#	Article	IF	Citations
187	Sleep apnea as a comorbidity in obese psoriasis patients: a crossâ€sectional study. Do psoriasis characteristics and metabolic parameters play a role?. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 820-826.	1.3	39
188	Association of chronic plaque psoriasis and severe periodontitis: a hospital based caseâ€control study. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 967-972.	1.3	35
189	Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. Immunologic Research, 2013, 56, 382-389.	1.3	46
190	The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. Journal of Gastroenterology, 2013, 48, 839-846.	2.3	70
191	Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 12-29.	1.3	248
193	The dermatological consequences of obesity. International Journal of Dermatology, 2013, 52, 927-932.	0.5	19
194	Biological therapies for psoriasis. Expert Opinion on Biological Therapy, 2013, 13, 1715-1730.	1.4	23
195	Psoriasis and hemorheology. Influence of the metabolic syndrome. Clinical Hemorheology and Microcirculation, 2013, 55, 331-339.	0.9	8
196	Platelet activation: a link between psoriasisper seand subclinical atherosclerosis - a case-control study. British Journal of Dermatology, 2013, 169, 68-75.	1.4	47
198	Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. British Journal of Dermatology, 2013, 169, 783-793.	1.4	124
199	Erythrocyte deformability and psoriasis. Clinical Hemorheology and Microcirculation, 2013, 55, 277-280.	0.9	1
200	Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1387-1404.	1.3	105
201	Psoriasis y su relaciÃ³n con el sÃndrome metabÃ³lico. Revista Colombiana De ReumatologÃa, 2013, 20, 228-236.	0.0	1
202	Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis. Fertility and Sterility, 2013, 99, 936-942.	0.5	23
203	Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study. International Journal of Dermatology, 2013, 52, 314-322.	0.5	27
204	Cardiovascular aspects of psoriasis: an updated review. International Journal of Dermatology, 2013, 52, 153-162.	0.5	52
205	Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. Journal of the American Academy of Dermatology, 2013, 68, 654-662.	0.6	327
206	Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Annals of the Rheumatic Diseases, 2013, 72, 1956-1961.	0.5	96

#	Article	IF	Citations
208	The Prevalence of Systemic Diseases Associated with Dermatoses and Stroke in the United States: A Cross-Sectional Study. Dermatology, 2013, 227, 330-337.	0.9	4
209	Cumulative Life Course Impairment: Evidence for Psoriasis. Current Problems in Dermatology, 2013, 44, 82-90.	0.8	38
210	Psoriasis Is Not Associated with Atherosclerosis and Incident Cardiovascular Events: The Rotterdam Study. Journal of Investigative Dermatology, 2013, 133, 2347-2354.	0.3	102
211	A Clinical and Epidemiological Study of Psoriasis and its Association with Various Biochemical Parameters in Newly Diagnosed Cases. Journal of Clinical and Diagnostic Research JCDR, 2013, 7, 2901-3.	0.8	2
212	The Effect of Weight Loss in Obese Patients with Chronic Stable Plaque-Type Psoriasis. Dermatology Research and Practice, 2013, 2013, 1-5.	0.3	20
213	Examining the Risk of Cardiovascular Disease in Patients with Psoriasis: A Critical Review. Journal of Cutaneous Medicine and Surgery, 2013, 17, 89-105.	0.6	6
214	Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis. Journal of Investigative Dermatology, 2013, 133, 2340-2346.	0.3	224
215	Comorbidities of psoriasis. Expert Review of Dermatology, 2013, 8, 277-290.	0.3	2
216	Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy. Psoriasis: Targets and Therapy, 2013, , 1.	1.2	5
217	Coâ€morbidities in psoriasis: a hospitalâ€based caseâ€control study. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1417-1425.	1.3	16
218	Psoriasis in children: should we be worried about comorbidities?. British Journal of Dermatology, 2013, 168, 661-663.	1.4	7
219	Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. British Journal of Dermatology, 2013, 168, 749-755.	1.4	65
220	Localized depigmentation on genital melanosis: a clue for the understanding of vitiligo. British Journal of Dermatology, 2013, 168, 663-664.	1.4	9
221	Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. British Journal of Dermatology, 2013, 168, 1124-1127.	1.4	67
222	Metabolic syndrome in psoriatic arthritis patients: A cross-sectional study. International Journal of Rheumatic Diseases, 2013, 16, 667-673.	0.9	22
223	A marriage of two â€œMethusalemâ€•drugs for the treatment of psoriasis?. Dermato-Endocrinology, 2013, 5, 252-263.	1.9	24
224	Metabolisches Syndrom bei unbehandelten Psoriasispatienten: eine Fall-Kontroll-Studie. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1169-1176.	0.4	1
225	Metabolic syndrome in untreated patients with psoriasis: caseâ€control study. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1169-1175.	0.4	14

#	Article	IF	Citations
226	An Observational Study on the Obesity and Metabolic Status of Psoriasis Patients. Annals of Dermatology, 2013, 25, 440.	0.3	20
227	Psoriasis: A Disease of Systemic Inflammation with Comorbidities. , 2013, , .		1
228	Psoriasis as a disease associated with the immune system disorders. Central-European Journal of Immunology, 2013, 1, 129-133.	0.4	2
229	Lipid Profile and Metabolic Syndrome Status in Patients with Oral Lichen Planus, Oral Lichenoid Reaction and Healthy Individuals Attending a Dental College in Northern India - A Descriptive Study. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, ZC92-5.	0.8	19
230	Metabolic syndrome and its components in patients with psoriasis. SpringerPlus, 2014, 3, 612.	1.2	21
231	Metabolic syndrome in patients with psoriasis: A comparative study. Indian Dermatology Online Journal, 2014, 5, 132.	0.2	20
232	Implementing Best Practice in Psoriasis: A Nordic Expert Group Consensus. Acta Dermato-Venereologica, 2014, 94, 547-552.	0.6	13
233	Metabolic Changes and Serum Ghrelin Level in Patients with Psoriasis. Dermatology Research and Practice, 2014, 2014, 1-6.	0.3	6
234	Dyslipidemia in Psoriasis: A Case Controlled Study. International Scholarly Research Notices, 2014, 2014, 1-5.	0.9	11
235	The Influence of Body Weight on the Prevalence and Severity of Hidradenitis Suppurativa. Acta Dermato-Venereologica, 2014, 94, 553-557.	0.6	155
236	Cardiovascular Risk Factors in Children and Adolescents with Psoriasis: A Case-control Study. Acta Dermato-Venereologica, 2014, 94, 76-78.	0.6	16
238	Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal Î³Î´ T-cell number: a prospective case-series study. British Journal of Dermatology, 2014, 171, 155-161.	1.4	44
239	A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. Pharmacogenomics Journal, 2014, 14, 523-525.	0.9	19
240	Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1186-1191.	1.3	24
241	Body mass index, waist circumference and HOMA-IR correlate with the Psoriasis Area and Severity Index in patients with psoriasis receiving phototherapy. British Journal of Dermatology, 2014, 171, 436-438.	1.4	18
242	Hyperuricemia in Patients with Chronic Plaque Psoriasis. Drug Development Research, 2014, 75, S70-2.	1.4	10
243	Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema. Science Translational Medicine, 2014, 6, 244ra90.	5.8	170
244	Psoriasis and comorbidities: links and risks. Clinical, Cosmetic and Investigational Dermatology, 2014, 7, 119.	0.8	105

#	Article	IF	Citations
245	Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 333-337.	1.3	217
246	Hyperuricemia in patients with chronic plaqueÂpsoriasis. Journal of the American Academy of Dermatology, 2014, 70, 127-130.	0.6	45
247	Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy. Dermatology and Therapy, 2014, 4, 1-9.	1.4	30
248	Psoriasis as a systemic disease. Clinics in Dermatology, 2014, 32, 343-350.	0.8	126
249	Increased prevalence of psoriasis in patients with coronary artery disease: results from a caseâ€“control study. British Journal of Dermatology, 2014, 171, 580-587.	1.4	15
250	Higher Rates and Clustering of Abnormal Lipids, Obesity, and Diabetes Mellitus in Psoriatic Arthritis Compared With Rheumatoid Arthritis. Arthritis Care and Research, 2014, 66, 600-607.	1.5	121
251	Psoriasis beyond the skin: a review of the literature on cardiometabolic and psychological co-morbidities of psoriasis. European Journal of Dermatology, 2014, 24, 305-311.	0.3	30
252	Severe androgenetic alopecia as a proxy of metabolic syndrome in male psoriatic patients older than 59 years. European Journal of Dermatology, 2014, 24, 356-360.	0.3	4
253	Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. Journal of Dermatological Treatment, 2014, 25, 470-481.	1.1	16
255	Psoriasis: guidance on assessment and referral. Clinical Medicine, 2014, 14, 178-182.	0.8	12
256	Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients. Clinical Rheumatology, 2014, 33, 1759-1764.	1.0	27
257	Biomedical Literature Mining. Methods in Molecular Biology, 2014, , .	0.4	6
258	Metabolic Syndrome Prevalence in Psoriasis. American Journal of Clinical Dermatology, 2014, 15, 371-377.	3.3	32
259	Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial. Clinical Nutrition, 2014, 33, 399-405.	2.3	71
260	Assessment of Atrial Electromechanical Delay and Pâ€Wave Dispersion in Patients with Psoriasis. Echocardiography, 2014, 31, 1071-1076.	0.3	15
261	High Prevalence of Metabolic Syndrome and of Insulin Resistance in Psoriatic Arthritis is Associated with the Severity of Underlying Disease. Journal of Rheumatology, 2014, 41, 1357-1365.	1.0	135
262	Mild Cognitive Impairment in Patients with Moderate to Severe Chronic Plaque Psoriasis. Dermatology, 2014, 228, 78-85.	0.9	51
263	Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis. Journal of Internal Medicine, 2015, 278, 660-670.	2.7	22

#	Article	IF	Citations
264	Hidradenitis suppurativa and metabolic syndrome: a comparative crossâ€sectional study of 3207 patients. British Journal of Dermatology, 2015, 173, 464-470.	1.4	128
265	Nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1154-1160.	0.8	23
266	Non-alcoholic fatty liver disease and psoriasis: So far, so near. World Journal of Hepatology, 2015, 7, 315.	0.8	51
267	The association between smoking and the prevalence of metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years. Postepy Dermatologii I Alergologii, 2015, 5, 331-336.	0.4	14
268	PERFIL NUTRICIONAL E CONSUMO DE ALIMENTOS INFLAMATÃ“RIOS E ANTI-INFLAMATÃ“RIOS DE PACIENTES ATENDIDOS NO AMBULATÃ“RIO DE PSORÃ•ASE DE UMA UNIDADE DE SAÃšDE-ESCOLA DE ITAJAÃ, SC. DEMETRA: AlimentaÃ§Ã£o, NutriÃ§Ã£o & SaÃºde, 2015, 10, .	0.2	2
269	Original paper Prevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years. Postepy Dermatologii I Alergologii, 2015, 4, 290-295.	0.4	20
270	Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities. Frontiers in Medicine, 2015, 2, 1.	1.2	68
272	Measuring psoriatic disease in clinical practice. An expert opinion position paper. Autoimmunity Reviews, 2015, 14, 864-874.	2.5	25
273	Psoriasis. Lancet, The, 2015, 386, 983-994.	6.3	1,793
274	Psoriasis and Metabolic Syndrome. Medicinski Arhiv = Medical Archives = Archives De MÃ©decine, 2015, 69, 85.	0.4	44
275	Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study. Journal of Dermatological Treatment, 2015, 26, 318-325.	1.1	12
276	Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation. IJC Metabolic & Endocrine, 2015, 6, 43-54.	0.5	16
277	Association between psoriasis, diabetes mellitus, hypertension and obesity. Clinical Epidemiology and Global Health, 2015, 3, 132-136.	0.9	1
278	Epigenetics in Psoriasis. , 2015, , 227-248.		1
279	Psoriasis: classical and emerging comorbidities. Anais Brasileiros De Dermatologia, 2015, 90, 9-20.	0.5	266
280	Effect of psoriasis activity on serum adiponectin and leptin levels. Postepy Dermatologii I Alergologii, 2015, 2, 101-106.	0.4	43
281	Psoriasis and polycystic ovary syndrome: a new link in different phenotypes. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 191, 101-105.	0.5	6
282	Association between psoriasis and asthma: a population-based retrospective cohort analysis. British Journal of Dermatology, 2015, 172, 1066-1071.	1.4	26

#	Article	IF	Citations
283	Homocysteine plasma levels in psoriasis patients: our experience and review of the literature. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1781-1785.	1.3	43
284	Prevalence of Metabolic Syndrome in Patients with Mucosal Lichen Planus: A Caseâ€“Control Study. American Journal of Clinical Dermatology, 2015, 16, 439-445.	3.3	30
285	Etiology and Pathogenesis of Psoriasis. Rheumatic Disease Clinics of North America, 2015, 41, 665-675.	0.8	130
286	Biomarkers of An Autoimmune Skin Diseaseâ€”Psoriasis. Genomics, Proteomics and Bioinformatics, 2015, 13, 224-233.	3.0	82
287	Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 955-963.	1.3	81
288	Personal history of gallstones and risk of incident psoriasis and psoriatic arthritis in U.S. women. British Journal of Dermatology, 2015, 172, 1316-1322.	1.4	10
289	Psoriasis and the Life Cycle of Persistent Life Effects. Dermatologic Clinics, 2015, 33, 25-39.	1.0	28
290	Serum adiponectin and leptin levels in psoriatic patients according to topical treatment. Journal of Dermatological Treatment, 2015, 26, 134-138.	1.1	21
291	Factors associated with the prescription of â€œtraditionalâ€•or â€œbiologicalâ€•systemic treatment in psoriasis. Journal of Dermatological Treatment, 2015, 26, 37-40.	1.1	4
292	Clinico-Biochemical Correlation Between Psoriasis and Insulin Resistance. Indian Journal of Clinical Biochemistry, 2015, 30, 99-103.	0.9	6
293	Assessment of arterial stiffness and cardiovascular hemodynamics by oscillometric method in psoriasis patients with normal cardiac functions. Heart and Vessels, 2015, 30, 347-354.	0.5	26
294	The Association between Psoriasis Area and Severity Index and Cardiovascular Risk Factor in Korean Psoriasis Patients. Annals of Dermatology, 2016, 28, 360.	0.3	10
295	Cardio Metabolic Syndrome: A Global Epidemic. Journal of Diabetes & Metabolism, 2016, 6, .	0.2	23
296	Psoriasis comorbidities: complications and benefits of immunobiological treatment. Anais Brasileiros De Dermatologia, 2016, 91, 781-789.	0.5	31
297	Assessment of adiposity in psoriatic patients by dual energy X-ray absorptiometry compared to conventional methods. Anais Brasileiros De Dermatologia, 2016, 91, 150-155.	0.5	5
298	Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background. World Journal of Cardiology, 2016, 8, 120.	0.5	36
299	Korea Blood Cancer Association: for supporting the patients suffering from blood cancers. Blood Research, 2016, 51, 72.	0.5	0
300	Liver Stiffness Measurement in Psoriasis: Do Metabolic or Disease Factors Play the Important Role?. BioMed Research International, 2016, 2016, 1-6.	0.9	28

#	Article	IF	Citations
301	Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug Design, Development and Therapy, 2016, 10, 1763.	2.0	26
302	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. International Journal of Molecular Sciences, 2016, 17, 217.	1.8	73
303	Relationship between psoriasis and non-alcoholic fatty liver disease. Przeglad Gastroenterologiczny, 2016, 4, 263-269.	0.3	11
304	Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis. Drug Design, Development and Therapy, 2016, 10, 533.	2.0	37
305	Distinguishing features of body mass index and psoriasis in men and women in Japan: A hospitalâ€based caseâ€“control study. Journal of Dermatology, 2016, 43, 1406-1411.	0.6	29
306	Metabolic syndrome in <scp>M</scp>oroccan patients with psoriasis. International Journal of Dermatology, 2016, 55, 396-400.	0.5	22
307	Nonâ€alcoholic fatty liver disease fibrosis score in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 282-287.	1.3	50
308	Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolic syndrome. Preliminary report. Cytokine, 2016, 85, 130-136.	1.4	26
309	The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, butÂwith Key Differences in Immune Regulatory Genes. Journal of Investigative Dermatology, 2016, 136, 2173-2182.	0.3	47
310	Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis. Atherosclerosis, 2016, 251, 25-30.	0.4	47
311	A multileveled approach in psoriasis assessment and follow-up: A proposal for a tailored guide for the dermatological practice. Journal of Dermatological Treatment, 2016, 27, 298-310.	1.1	9
312	Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity. JAMA Dermatology, 2016, 152, 761.	2.0	65
313	Association Between Pediatric Psoriasis and Waist-to-Height Ratio in the Absence of Obesity. JAMA Dermatology, 2016, 152, 1314.	2.0	17
314	A prospective phase III, randomized, doubleâ€blind, placeboâ€controlled study of brodalumab in patients with moderateâ€toâ€severe plaque psoriasis. British Journal of Dermatology, 2016, 175, 273-286.	1.4	378
315	Evaluation of Cardiovascular Risk Factors, Haematological and Biochemical Parameters, and Serum Endocan Levels in Patients with Lichen Planus. Dermatology, 2016, 232, 438-443.	0.9	10
316	Neutrophil extracellular trap formation is increased in psoriasis and induces human Î²-defensin-2 production in epidermal keratinocytes. Scientific Reports, 2016, 6, 31119.	1.6	146
317	Upregulation of ANGPTL6 in mouse keratinocytes enhances susceptibility to psoriasis. Scientific Reports, 2016, 6, 34690.	1.6	12
318	Glomerular filtration rate in patients with psoriasis treated with etanercept. Journal of International Medical Research, 2016, 44, 106-108.	0.4	8

#	Article	IF	Citations
319	Clinical and cytokine profile evaluation in Northeast Brazilian psoriasis plaque-type patients. European Cytokine Network, 2016, 27, 1-5.	1.1	23
320	Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Review of Clinical Immunology, 2016, 12, 1299-1308.	1.3	67
321	Carotid intimaâ€“media thickness, nonalcoholic fatty liver disease, and hemoglobin A1c are independently associated with the severity of psoriasis. Dermatologica Sinica, 2016, 34, 135-140.	0.2	2
322	Los 10 diagnÃ³sticos mÃ¡s frecuentes en dermatologÃa. FMC Formacion Medica Continuada En Atencion Primaria, 2016, 23, 119-141.	0.0	0
323	High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study. International Journal of Dermatology, 2016, 55, 390-395.	0.5	26
324	Serum Preptin and Amylin Values in Psoriasis Vulgaris and BehÃ§et's Patients. Journal of Clinical Laboratory Analysis, 2016, 30, 165-168.	0.9	7
325	Impact of smoking on disease severity in patients with plaque type psoriasis. Turkderm, 2016, 49, 19-22.	0.0	3
326	Biomarkers of Metabolic Syndrome: Biochemical Background and Clinical Significance. Metabolic Syndrome and Related Disorders, 2016, 14, 47-93.	0.5	26
327	Erectile dysfunction in patients with plaque psoriasis: the relation of depression and cardiovascular factors. International Journal of Impotence Research, 2016, 28, 96-100.	1.0	28
328	Prevalence of metabolic syndrome as per the NCEP and IDF definitions vis-a-vis severity and duration of psoriasis in a semi-urban Maharashtrian population: A case control study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016, 10, S72-S76.	1.8	15
329	Study of endothelial dysfunction in patients of psoriatic arthritis by flow mediated and nitroglycerine mediated dilatation of brachial artery. International Journal of Rheumatic Diseases, 2016, 19, 300-304.	0.9	13
330	Prevalence of obesity in paediatric psoriasis and its impact on disease severity and progression. Australasian Journal of Dermatology, 2017, 58, e182-e187.	0.4	14
331	Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients. Archives of Dermatological Research, 2017, 309, 79-86.	1.1	50
332	Safety evaluation of apremilast for the treatment of psoriasis. Expert Opinion on Drug Safety, 2017, 16, 381-385.	1.0	20
333	Efficacy of oxymatrine for treatment and relapse suppression of severe plaque psoriasis: results from a single-blinded randomized controlled clinical trial. British Journal of Dermatology, 2017, 176, 1446-1455.	1.4	16
334	â€˜New to meâ€™: changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well^{Â®}patient materials mixedâ€methods feasibility study. British Journal of Dermatology, 2017, 177, 758-770.	1.4	25
335	Risk of developing psoriasis in patients with schizophrenia: a nationwide retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1497-1504.	1.3	29
336	Immunopathogenesis of Psoriasis. , 2017, , 373-395.		4

#	Article	IF	Citations
337	Obesity, Type 1 Diabetes, and Psoriasis: An Autoimmune Triple Flip. Pathobiology, 2017, 84, 71-79.	1.9	33
338	â€œInflammatory skin marchâ€•in atopic dermatitis and psoriasis. Inflammation Research, 2017, 66, 833-842.	1.6	71
339	Serum fatty acid profile in psoriasis and its comorbidity. Archives of Dermatological Research, 2017, 309, 371-380.	1.1	45
340	Is psoriasis an independent risk factor of renal disease? A nationwide retrospective cohort study from 1996 to 2010. Dermatologica Sinica, 2017, 35, 78-84.	0.2	28
341	Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. American Journal of the Medical Sciences, 2017, 354, 172-181.	0.4	56
342	Cardiovascular Risk Factors and Carotid Intima-Media Thickness in a Colombian Population With Psoriasis. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 738-745.	0.2	1
344	Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. Journal of the American Academy of Dermatology, 2017, 77, 657-666.e8.	0.6	96
345	Factores de riesgo cardiovascular y grosor de la Ãntima media carotÃdea en una poblaciÃ³n colombiana con psoriasis. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 738-745.	0.2	8
346	Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments. Drugs and Aging, 2017, 34, 583-588.	1.3	10
347	Insights into gene expression profiles induced by Socs3 depletion in keratinocytes. Scientific Reports, 2017, 7, 15830.	1.6	6
348	Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. Annual Review of Medicine, 2017, 68, 255-269.	5.0	134
349	Co-morbidity in psoriasis: mechanisms and implications for treatment. Expert Review of Clinical Immunology, 2017, 13, 27-34.	1.3	26
350	UnerwÃ¼nschte Wirkungen von Biologika bei Psoriasis. Karger Kompass Dermatologie, 2017, 5, 195-199.	0.0	1
351	Association between mean platelet volume and disease severity in patients with psoriasis and psoriatic arthritis. Postepy Dermatologii I Alergologii, 2017, 2, 126-130.	0.4	24
352	Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis. Acta Dermato-Venereologica, 2017, 97, 782-787.	0.6	30
353	Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin. Internal Medicine, 2017, 56, 1613-1619.	0.3	49
354	Effect of Diet and Exercise on Plaque Psoriasis in Children. British Journal of Research, 2017, 04, .	0.1	0
355	Association of Metabolic Syndrome in Chronic Plaque Psoriasis Patients and their Correlation with Disease Severity, Duration and Age: A Case Control Study from Western Maharashtra. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, WC06-WC10.	0.8	10

#	Article	IF	Citations
356	Untargeted serum metabonomics study of psoriasis vulgaris based on ultra-performance liquid chromatography coupled to mass spectrometry. Oncotarget, 2017, 8, 95931-95944.	0.8	12
357	Association Between Metabolic Syndrome and Benign Prostate Hyperplasia. Bangladesh Journal of Medical Biochemistry, 2017, 8, 42-48.	0.2	0
358	Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study. Anais Brasileiros De Dermatologia, 2017, 92, 46-51.	0.5	38
359	Plasma homocysteine levels in patients with Psoriasis. Asian Journal of Medical Sciences, 2017, 8, 4-7.	0.0	4
360	Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget, 2017, 8, 46381-46389.	0.8	44
361	Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clinical Rheumatology, 2018, 37, 579-586.	1.0	43
362	Metabolic syndrome and the skin: a more than superficial association. Reviewing the association between skin diseases and metabolic syndrome and a clinical decision algorithm for high risk patients. Diabetology and Metabolic Syndrome, 2018, 10, 9.	1.2	63
363	Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. Experimental Dermatology, 2018, 27, 409-417.	1.4	143
364	Prevalence of metabolic syndrome in Chinese psoriasis patients: A hospitalâ€based crossâ€sectional study. Journal of Diabetes Investigation, 2018, 9, 39-43.	1.1	28
365	Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. Journal of the American Academy of Dermatology, 2018, 78, 323-332.	0.6	73
366	Adverse Reactions to Biologics in Psoriasis. Current Problems in Dermatology, 2018, 53, 1-14.	0.8	20
367	Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?. British Journal of Dermatology, 2018, 179, 16-29.	1.4	46
368	Interleukinâ€17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Experimental Dermatology, 2018, 27, 115-123.	1.4	97
369	Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: The Rotterdam Study. Journal of the American Academy of Dermatology, 2021, 85, 671-680.	0.6	27
370	Psoriasis and Cardiovascular Diseases: A Literature Review to Determine the Causal Relationship
. Cureus, 2018, 10, e2195.	0.2	25
371	Metabolic syndrome, C-reactive protein and cardiovascular risk in psoriasis patients: a cross-sectional study. Anais Brasileiros De Dermatologia, 2018, 93, 222-228.	0.5	16
372	The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor ï¡ in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis. Postepy Dermatologii I Alergologii, 2018, 35, 360-366.	0.4	25
373	Common Skin Disorders in the Elderly. , 2018, , 783-794.		0

#	Article	IF	Citations
374	Central Obesity in Children with Psoriasis. Acta Dermato-Venereologica, 2018, 98, 282-283.	0.6	20
375	Prevalence of smoking, alcohol consumption and metabolic syndrome in patients with psoriasis. Anais Brasileiros De Dermatologia, 2018, 93, 205-211.	0.5	28
376	Gender Differences in Psoriasis. , 2018, , 63-81.		2
377	Psoriasis: Psychosomatic, somatopsychic, or both?. Clinics in Dermatology, 2018, 36, 698-703.	0.8	13
378	Psoriasis and Psoriatic Spectrum Disease: A Primer for the Primary Care Physician. American Journal of Medicine, 2018, 131, 1146-1154.	0.6	9
379	Role of galectinâ€3 in subclinical myocardial impairment in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 136-142.	1.3	11
380	Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clinical Rheumatology, 2019, 38, 2843-2850.	1.0	39
381	Evaluation of Psoriasis Patients. , 0, , .		0
382	The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. Expert Opinion on Drug Safety, 2019, 18, 1031-1041.	1.0	12
383	HLA Correlations with Clinical Phenotypes and Risk of Metabolic Comorbidities in Singapore Chinese Psoriasis Patients. Molecular Diagnosis and Therapy, 2019, 23, 751-760.	1.6	8
384	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. International Journal of Environmental Research and Public Health, 2019, 16, 3415.	1.2	90
385	The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1405-1412.	1.8	28
386	High burden of the metabolic syndrome and its component disorders in South Africans with psoriasis. International Journal of Dermatology, 2019, 58, 557-562.	0.5	15
387	Current understanding of the role of dietary lipids in the pathophysiology of psoriasis. Journal of Dermatological Science, 2019, 94, 314-320.	1.0	20
388	Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters. Turkish Journal of Medical Sciences, 2019, 49, 110-115.	0.4	2
389	Glomerular filtration rate in patients with moderateâ€toâ€severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e244-e246.	1.3	4
390	Psorijaza â€“ vidljivi ubojica. Medicina Fluminensis, 2019, 55, 215-223.	0.1	0
391	Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence. Journal of Dermatology, 2019, 46, 3-10.	0.6	25

#	Article	IF	Citations
392	Psoriasis and cardiovascular disease: the elusive link. International Reviews of Immunology, 2019, 38, 33-54.	1.5	32
393	The multifaceted association between psoriasis and obesity. British Journal of Dermatology, 2019, 180, 24-24.	1.4	2
394	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. Journal of the American Academy of Dermatology, 2019, 80, 251-265.e19.	0.6	362
395	Phototherapy decreases red blood cell deformability in patients with psoriasis. Clinical Hemorheology and Microcirculation, 2020, 73, 489-496.	0.9	2
396	Addressing Hypertension in Patients With Psoriasis: Review and Recommendations. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 129-138.	0.3	1
397	Moving cupping therapy for plaque psoriasis. Medicine (United States), 2020, 99, e22539.	0.4	4
398	Retrospective analysis of patients with psoriasis receiving biological therapy: <scp>Realâ€life</scp> data. Dermatologic Therapy, 2020, 33, e14336.	0.8	5
399	Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatologic Therapy, 2020, 33, e14281.	0.8	12
400	Very low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: an update for dermatologists and nutritionists. Critical Reviews in Food Science and Nutrition, 2022, 62, 398-414.	5.4	32
401	Impact of Psoriasis on Mortality Rate and Outcome in Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e016956.	1.6	19
402	High-throughput transcriptome and pathogenesis analysis of clinical psoriasis. Journal of Dermatological Science, 2020, 98, 109-118.	1.0	28
403	Proprotein Convertase Subtilisin/Kexin Type 9, Angiopoietin-Like Protein 8, Sortilin, and Cholesteryl Ester Transfer Proteinâ€"Friends of Foes for Psoriatic Patients at the Risk of Developing Cardiometabolic Syndrome?. International Journal of Molecular Sciences, 2020, 21, 3682.	1.8	14
404	An update on the safety of apremilast for the treatment of plaque psoriasis. Expert Opinion on Drug Safety, 2020, 19, 403-408.	1.0	4
405	Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report. BMC Neurology, 2020, 20, 106.	0.8	4
406	Higher incidence of metabolic syndrome components in vitiligo patients: a prospective cross-sectional study. Anais Brasileiros De Dermatologia, 2020, 95, 165-172.	0.5	30
407	Risk of Psoriasis in Patients with Polycystic Ovary Syndrome: A National Population-Based Cohort Study. Journal of Clinical Medicine, 2020, 9, 1947.	1.0	1
408	Higher bodily adiposity, fat intake, and cholesterol serum levels are associated with higher disease activity in psoriatic arthritis patients: is there a link among fat and skin and joint involvement?. Lipids in Health and Disease, 2020, 19, 21.	1.2	11
409	IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. Frontiers in Immunology, 2019, 10, 3096.	2.2	122

#	Article	IF	Citations
410	A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn's disease receiving methotrexate therapy. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 100003.	0.7	14
411	Association of Birth Weight, Childhood Body Mass Index, and Height With Risk of Hidradenitis Suppurativa. JAMA Dermatology, 2020, 156, 746.	2.0	12
412	Chronic kidney disease in psoriasis: a cohort study. JDDG - Journal of the German Society of Dermatology, 2020, 18, 438-445.	0.4	11
413	Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). Journal of the American Academy of Dermatology, 2021, 84, 398-407.	0.6	11
414	Role of Lipid and Oxidative Stress in Psoriatic Patients - A Case Control Study. Journal of Evolution of Medical and Dental Sciences, 2021, 10, 132-136.	0.1	0
415	Metabolic syndrome and insulin resistance in pre-pubertal children with psoriasis. European Journal of Pediatrics, 2021, 180, 1739-1745.	1.3	13
416	Association between acidâ€suppressive drug use and atopic dermatitis in patients with upper gastrointestinal diseases: A populationâ€based retrospective cohort study. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 786-793.	0.7	1
417	Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges. American Journal of Clinical Dermatology, 2021, 22, 293-300.	3.3	10
418	Nextâ€generation sequencing of the whole mitochondrial genome identifies novel and common variants in patients with psoriasis, type 2 diabetes mellitus and psoriasis with comorbid type 2 diabetes mellitus. Biomedical Reports, 2021, 14, 41.	0.9	4
419	Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis. Molecular Biology Reports, 2021, 48, 4421-4429.	1.0	6
420	Acne and itch: Pathogenic role of neurogenic inï¬,ammation. Medical Alphabet, 2022, , 7-11.	0.0	0
421	Serum lactate dehydrogenase level as a possible predictor of treatment preference in psoriasis. Journal of Dermatological Science, 2021, 103, 109-115.	1.0	5
422	Does Age Matter in Psoriatic Arthritis? A Narrative Review. Journal of Rheumatology, 2022, 49, 1085-1091.	1.0	13
423	Psoriasis comorbidities and clinical implications when using biologics. Dermatological Reviews, 0, , .	0.3	1
425	Grosor de intima-media carotÃ¡dea en pacientes con psoriasis con y sin sÃ¡ndrome metabÃ³lico. Archivos De Cardiologia De Mexico, 2021, 92, .	0.1	3
426	Chemerin activity in selected pathological states of human body â€“ A systematic review. Advances in Medical Sciences, 2021, 66, 270-278.	0.9	7
427	Burden of Disease for Psoriasis in Argentina, Brazil, Colombia, and Mexico. Value in Health Regional Issues, 2021, 26, 126-134.	0.5	1
428	Geriatric Dermatology. , 2021, , 355-379.		0

#	Article	IF	Citations
429	Mining Emerging Biomedical Literature for Understanding Disease Associations in Drug Discovery. Methods in Molecular Biology, 2014, 1159, 171-206.	0.4	9
430	Adipose Tissue and Cutaneous Inflammation. , 2017, , 219-238.		3
432	Prevalence of metabolic syndrome in patients with psoriasis: a cross-sectional study in Singapore. Singapore Medical Journal, 2020, 61, 194-199.	0.3	9
433	Psoriasis and Hypertension Severity: Results from a Case-Control Study. PLoS ONE, 2011, 6, e18227.	1.1	78
434	Increased Prevalence of Metabolic Syndrome in Patients with Acne Inversa. PLoS ONE, 2012, 7, e31810.	1.1	197
435	An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS ONE, 2017, 12, e0181039.	1.1	79
436	A Study of Intima Media Thickness and Their Cardiovascular Risk Factors in Patients with Psoriatic Arthritis. Acta Medica (Hradec Kralove), 2009, 52, 107-116.	0.2	20
437	Heart rate variability in patients with psoriatic arthritis: associations with systemic inflammation and traditional cardiovascular risk factors. Cardiovascular Therapy and Prevention (Russian Federation), 2011, 10, 88-92.	0.4	1
438	Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients. European Journal of Dermatology, 2020, 30, 159-164.	0.3	2
439	Psoriasis and fatty liver: a harmful synergy. Revista Espanola De Enfermedades Digestivas, 2019, 111, 314-319.	0.1	13
440	Personalized Medicine in Psoriasis: Concept and Applications. Current Vascular Pharmacology, 2010, 8, 432-436.	0.8	8
441	The Association of Metabolic Syndrome and Psoriasis: A Systematic Review and Meta-Analysis of Observational Study. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 703-717.	0.6	34
442	Higher Risk of Future Cardiovascular Events Among Patients with Psoriatic Arthritis Compared to Psoriatic Patients Between the Ages of 30-50. Open Dermatology Journal, 2018, 12, 5-11.	0.5	2
443	Prevalence of metabolic syndrome in Montenegrin patients with psoriasis. Vojnosanitetski Pregled, 2016, 73, 1016-1021.	0.1	6
444	Effects of TNFÎ± inhibitors in patients with psoriasis and metabolic syndrome: a preliminary study. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 14-18.	0.8	8
445	Psoriasis as a cardiovascular risk factor: updates and algorithmic approach. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 659-665.	0.8	7
446	Prevalencia del sÃ¬ndrome metabÃ³lico, gravedad clÃ¬nica y calidad de vida en pacientes con psoriasis del Hospital Universitario de La Samaritana. Revista De La AsociaciÃ³n Colombiana De DermatologÃa Y CirugÃa DermatolÃ³gica, 2013, 21, 220-225.	0.0	7
447	Abnormal Serum Lipid Profile and Smoking are Associated with Plaque-type Psoriasi: A Case Control Study. Journal of Medical Sciences (Faisalabad, Pakistan), 2014, 14, 217-222.	0.0	2

#	Article	IF	Citations
448	Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. American Journal of Clinical Nutrition, 2008, 88, 1242-7.	2.2	214
449	Prevalence of metabolic syndrome in south Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome: A hospital-based case-control study. Indian Journal of Dermatology, 2012, 57, 353.	0.1	47
450	Metabolic syndrome and skin: Psoriasis and beyond. Indian Journal of Dermatology, 2013, 58, 299.	0.1	51
451	Psoriasis and cardiomyopathy: An intriguing association. Indian Journal of Dermatology, 2010, 55, 271.	0.1	7
452	A study of the prevalence of diabetes, insulin resistance, lipid abnormalities, and cardiovascular risk factors in patients with chronic plaque psoriasis. Indian Journal of Dermatology, 2011, 56, 520.	0.1	35
453	Dyslipidemia in dermatological disorders. North American Journal of Medical Sciences, 2015, 7, 421.	1.7	34
454	Assessment of the Possible Role of FOXP3 Gene (rs3761548) Polymorphism in Psoriasis Vulgaris Susceptibility and Pathogenesis: Egyptian Study. Indian Dermatology Online Journal, 2019, 10, 401.	0.2	8
455	Prevalence of metabolic syndrome in psoriasis and levels of Interleukin-6 and tumor necrosis factor-Î± in psoriasis patients with metabolic syndrome: Indian Tertiary Care Hospital study. International Journal of Applied & Basic Medical Research, 2017, 7, 169.	0.2	8
456	A Review on Underlying Differences in the Prevalence of Metabolic Syndrome in the Middle East, Europe and North America. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2014, 02, .	0.1	7
457	Evaluation of Soluble P-selectin and Leptin Serum Levels in Sera of Patients of Psoriasis and their Possible Role in the Increase in the Cardiovascular Risks in Psoriatic Patients. Journal of Clinical & Experimental Dermatology Research, 2014, 05, .	0.1	3
458	More than skin-deep: the many dimensions of the psoriatic disease. Swiss Medical Weekly, 2014, 144, w13968.	0.8	23
459	Psoriasis, a Systemic Disease?. Turk Dermatoloji Dergisi, 2012, 6, 123-126.	0.3	3
460	Double trouble: psoriasis and cardiometabolic disorders. Cardiovascular Journal of Africa, 2018, 29, 189-194.	0.2	4
461	Increased P-wave dispersion in patients with newly diagnosed lichen planus. Clinics, 2013, 68, 846-850.	0.6	15
462	Metabolic Syndrome in Psoriasis among Urban South Indians: A Case Control Study Using SAM-NCEP Criteria. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, WC01-WC04.	0.8	7
463	Predicting psoriasis using routine laboratory tests with random forest. PLoS ONE, 2021, 16, e0258768.	1.1	4
466	Metabolic Syndrome in Psoriasis. , 2010, , 95-98.		1
467	The Role of Cardiovascular Disease in the Patient with Psoriasis. Psoriasis Forum, 2011, 17a, 42-55.	0.1	0

#	Article	IF	Citations
468	NORMAS DE BOA PRÃ•TICA PARA O TRATAMENTO DA PSORÃ•ASE EM PLACAS EM IDADE NÃƒO PEDIÃ•TRICA COM BIOLÃ“GICOS. Journal of the Portuguese Society of Dermatology and Venereology, 2011, 69, 532.	0.0	2
469	JUSTIFICACIÃ“N DE LA IMPORTANCIA DE VALORAR EL RIESGO CARDIOVASCULAR EN PSORIASIS. , 2012, , 1-27.		0
470	Food, Nutrition and Diet Therapy in Psoriasis. , 0, , .		0
471	The Association Between Psoriasis and Cardiovascular Diseases. Electronic Journal of General Medicine, 2013, 10, .	0.3	1
473	Prevalencia de SÃ•ndrome metabÃ³lico en pacientes con psoriasis, mayores de 40 aÃ±os.. Revista MÃ©dica De Los Postgrados De Medicina, 2012, 13, .	0.0	1
475	Prevalence of metabolic syndrome in Psoriasis â€“ a case control study. International Journal of Medical Research and Review, 2015, 3, 404-408.	0.1	0
476	ONICOMICOSE E PSORÃ•ASE UNGUEAL. Journal of the Portuguese Society of Dermatology and Venereology, 2015, 73, 211-218.	0.0	0
477	HOSPITAL BASED STUDY ON DYSLIPIDEMIA AND PSORIASIS. Journal of Evolution of Medical and Dental Sciences, 2015, 4, 15224-15227.	0.1	0
478	A Study of Prevalence of Metabolic Syndrome in Patients of Psoriasis of North India. British Journal of Medicine and Medical Research, 2016, 11, 1-8.	0.2	1
479	Comorbidities, Metabolic and Malignancy Risk Profile in Patients with Psoriasis. West Indian Medical Journal, 0, , .	0.4	0
480	Psoriasis and metabolic syndrome: hospital based cross sectional study of prevalence and correlation in a rural south Indian population. International Journal of Research in Dermatology, 2016, 2, 49.	0.0	0
481	Psoriasis and Aging. , 2017, , 1065-1070.		0
482	Common Skin Disorders in the Elderly. , 2017, , 1-12.		0
483	Evaluation of atherosclerosis risk by measurement of intima media thickness and pulse wave velocity in lichen planus patients; A prospective case-control study. Journal of Surgery and Medicine, 0, , .	0.0	0
484	Preparation and Evaluation of Anti inflammatory Polyherbal Gel. American Journal of PharmTech Research, 2018, 8, 387-394.	0.2	0
485	PSORIASIS, PSORIATIC ARTHRITIS AND SECONDARY GOUT â€“ 3 CASE REPORTS. Journal of IMAB, 2018, 24, 1972-1877.	0.1	0
486	Metabolic Syndrome, Cardiovascular Disease and the Hair Growth Cycle: Addressing hair growth disruptions using NourkrinÂ® with MarilexÂ® as a proteoglycan replacement therapy: A concise review. , 2018, 2, 001-007.		0
487	Epitope spreading phenomenon: A case report. Indian Dermatology Online Journal, 2019, 10, 580.	0.2	1

#	Article	IF	Citations
488	VII. Obesity & Metabolic Syndrome in Psoriasis. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 708-714.	0.0	0
489	Dyslipidemia and Hyperglycemia in Psoriatic Inpatients. International Journal of Medical Students, 2019, 7, 62-65.	0.2	0
490	The evaluation of efficacy and safety of methotrexate and pioglitazone in psoriasis patients: A randomized, open-labeled, active-controlled clinical trial. Indian Journal of Pharmacology, 2020, 52, 16.	0.4	6
492	Folate Nutritional Status among Psoriasis Patients not Exposed to Antifolate Drug. Current Nutrition and Food Science, 2020, 16, 543-553.	0.3	0
493	Adherence to the Mediterranean diet model and psoriatic disease (skin, joint and metabolic expression) Tj ETQq0 0 0 rgBT /Overlock 10	0.3	0
494	A CLINICO-EPIDEMIOLOGICAL STUDY OF PSORIASIS IN A TERTIARY CARE HOSPITAL IN PATNA, BIHAR. , 2020, , 53-54.		0
495	Association between metabolic syndrome and psoriasis: a meta-analysis of observational studies with non-psoriasis control groups. Archives of Medical Science, 2020, 17, 1558-1565.	0.4	1
496	The role of non-invasive scores in determining the liver fibrosis in NAFLD and psoriatic patients. Romanian Journal of Morphology and Embryology, 2020, 61, 503-511.	0.4	4
497	Î²-Hydroxybutyrate Reduces Psoriasiform Dermatitis. Journal of St Marianna University, 2020, 11, 153-159.	0.1	0
498	Evaluation of the association of metabolic syndrome with psoriasis and its severity: A cross-sectional study. Indian Journal of Dermatology, 2020, 65, 243.	0.1	1
499	Psoriasis in patients with metabolic syndrome: clinical aspects of the problem. Klinicheskaya Dermatologiya I Venerologiya, 2020, 19, 214.	0.0	3
501	Psoriasis and Comorbidities. , 2021, , 363-397.		0
502	Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis. Ontario Health Technology Assessment Series, 2009, 9, 1-66.	3.0	5
503	Multifaceted Analysis of IL-23A- and/or EBI3-Including Cytokines Produced by Psoriatic Keratinocytes. International Journal of Molecular Sciences, 2021, 22, 12659.	1.8	6
504	Does the lifestyle of patients with psoriasis affect their illness?. Postepy Higieny I Medycyny Doswiadczalnej, 2021, 75, 643-654.	0.1	0
505	Nutritional implications for the pathophysiology and treatment of autoimmune disorders. , 2022, , 243-267.		0
506	Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review. Inflammation Research, 2022, 71, 157-168.	1.6	2
507	Prevalence of Atherosclerosis in Psoriatic Patients Detected with Epiaortic Color Doppler Ultrasound and Computed Tomography Angiography. Dermatology Practical and Conceptual, 2022, 12, e2022011.	0.5	1

#	Article	IF	Citations
508	Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 797-806.	1.3	36
509	Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. Programme Grants for Applied Research, 2022, 10, 1-240.	0.4	0
510	In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome. Pharmaceutical Research, 2022, , 1.	1.7	0
511	The Effect of Three-Month Vitamin D Supplementation on the Levels of Homocysteine Metabolism Markers and Inflammatory Cytokines in Sera of Psoriatic Patients. Biomolecules, 2021, 11, 1865.	1.8	9
512	Metabolic comorbidities of psoriasis (Review). Experimental and Therapeutic Medicine, 2021, 23, 179.	0.8	14
513	Age-specific prevalence of psoriasis in an unselected sample of 25,956 Italian hospital inpatients: evidence for selective excess mortality after 70 years of age. European Journal of Dermatology, 2018, 28, 103-105.	0.3	1
514	Evaluation of Oxidative Stress Marker and Ischemia Modified Albumin Levels in Patients with Psoriasis Vulgaris. Online TÃ¼rk SaÄŸlÄ±k Bilimleri Dergisi, 0, , .	0.1	0
515	4â€ƒThe psoriasiform reaction pattern. , 2010, , 49-67.		0
516	Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1969-1979.	1.3	12
517	Psoriatic arthritis and psoriasis severity as metabolic syndrome and insulin resistance predictors. Srpski Arhiv Za Celokupno Lekarstvo, 2022, 150, 456-461.	0.1	0
518	Prevalence of cardiovascular risk factors in patients with psoriasis. Central European Journal of Public Health, 2022, 30, S05-S10.	0.4	6
519	Abnormal inflammatory traits and downregulated caveolin-1 expression in monocytes of psoriasis patients may be associated with psoriatic inflammation and atherosclerosis. Journal of Dermatological Science, 2022, 107, 65-74.	1.0	5
520	Acute joint swelling in psoriatic arthritis: Flare or â€œpsoutâ€â€”A 10-year-monocentric study on synovial fluid. Experimental Biology and Medicine, 2022, 247, 1650-1656.	1.1	1
521	Metformin Inhibits HaCaT Cell Proliferation Under Hyperlipidemia Through Reducing Reactive Oxygen Species via FOXO3 Activation. Clinical, Cosmetic and Investigational Dermatology, 0, Volume 15, 1403-1413.	0.8	3
522	Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways. International Journal of Molecular Sciences, 2022, 23, 9063.	1.8	12
523	Evaluation of nonalcoholic fatty liver disease in Japanese patients with psoriasis: Chest <scp>CT</scp> imaging for screening purposes. Journal of Dermatology, 2022, 49, 1263-1267.	0.6	1
524	Psoriasis: Beyond the Skin. European Medical Journal (Chelmsford, England), 0, , 90-95.	3.0	0
525	Busting the myth of methotrexate chronic hepatotoxicity. Nature Reviews Rheumatology, 2023, 19, 96-110.	3.5	11

#	Article	IF	Citations
526	Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1). Dermatology and Therapy, 0, , .	1.4	0
527	The top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership. Rheumatology, 0, , .	0.9	1
528	Psoriasis and Comorbidities. EMJ Dermatology, 0, , 78-85.	0.0	1
529	The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease. Life, 2023, 13, 419.	1.1	8
530	Study protocol: Neuro-inflammatory parameters as mediators of the relationship between social anxiety and itch intensity: A cross-sectional, controlled laboratory study in patients with psoriasis and healthy skin controls. PLoS ONE, 2023, 18, e0281989.	1.1	1
531	Circulating ANGPTL8 as a Potential Protector of Metabolic Complications in Patients with Psoriasis. Journal of Clinical Medicine, 2023, 12, 2346.	1.0	0